A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
This study is testing different combinations of new drugs to see how well they treat advanced breast cancer that is sensitive to hormones. By combining these treatments, researchers hope to find more effective ways to slow down cancer growth and improve care for patients.
This study is for adults age 60 and older, or those who have gone through menopause and had their ovaries removed, who have ER+/HER2- breast cancer that has spread. You must not have received chemotherapy or certain specific targeted drugs for your advanced cancer previously.
Participants will receive a combination of the drug Elacestrant along with another targeted therapy to see which combinations work best and are safest. You will be closely monitored by a medical team throughout the study to track how your body responds to the treatment.
The study has locations in Dothan, Alabama; Phoenix, Arizona; and Springdale, Arkansas. It is currently active but is not looking for new participants at this time.
- 1Researchers are testing new ways to combine targeted therapies.
- 2The goal is to stop cancer cells from growing by blocking specific signals.
- 3Participants receive specialized care and monitoring from a dedicated research team.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.